Boston Scientific delivered strong Q4 2025 performance with robust revenue growth led by Cardiovascular, higher profitability, and adjusted EPS expansion.

Boston Scientific delivered a robust Q3 2025 performance, driven by significant revenue gains and higher net income, particularly in the U.S. and Cardiovascular segments.

Boston Scientific delivered a strong Q2 2025 with revenue surpassing $5 billion, driven by significant growth in the Cardiovascular segment. GAAP net income more than doubled year-over-year, and adjusted EPS exceeded guidance.

Boston Scientific delivered an impressive start to the year with $4.66 billion in revenue, a 20.9% increase year-over-year. Net income rose to $674 million, while adjusted EPS reached $0.75. The cardiovascular segment led performance with 25.6% organic growth, and U.S. sales jumped over 30%.

Boston Scientific reported a strong fourth quarter and full year 2024, with net sales reaching $4.561 billion in Q4, a 22.4% increase. The company's adjusted EPS for Q4 was $0.70, compared to $0.55 a year ago. Full year net sales were $16.747 billion, with adjusted EPS of $2.51.

Boston Scientific reported net sales of $4.209 billion, representing a 19.4% increase compared to the prior year period. The company's GAAP net income attributable to Boston Scientific common stockholders was $0.32 per share, and adjusted EPS was $0.63 per share.

Boston Scientific reported net sales of $4.120 billion for the second quarter of 2024, representing a 14.5% increase on a reported basis. The company's GAAP net income attributable to Boston Scientific common stockholders was $324 million, or $0.22 per share, and adjusted EPS was $0.62.

Boston Scientific reported net sales of $3.856 billion for Q1 2024, a 13.8% increase on a reported basis. GAAP net income attributable to Boston Scientific common stockholders was $495 million, or $0.33 per share, while adjusted EPS reached $0.56.

Boston Scientific announced net sales of $3.725 billion for Q4 2023, a 14.9% increase on a reported basis compared to the prior year period. GAAP net income attributable to Boston Scientific common stockholders was $504 million, or $0.34 per share, while adjusted EPS reached $0.55. The company exceeded its guidance range for both net sales growth and EPS.

Boston Scientific reported net sales of $3.527 billion for Q3 2023, an 11.2% increase year-over-year. GAAP net income attributable to Boston Scientific common stockholders was $505 million, or $0.34 per share, while adjusted EPS reached $0.50. The company's performance was attributed to its global team and differentiated medical technologies.

Boston Scientific reported net sales of $3.599 billion for Q2 2023, representing an 11.0% increase on a reported basis. The company's GAAP net income attributable to Boston Scientific common stockholders was $261 million, or $0.18 per share, and adjusted EPS was $0.53.

Boston Scientific reported net sales of $3.389 billion for the first quarter of 2023, representing a 12.0% increase on a reported basis. GAAP net income attributable to Boston Scientific common stockholders was $300 million, or $0.21 per share, while adjusted EPS reached $0.47.

Boston Scientific's Q4 2022 results showed a 3.7% increase in net sales to $3.242 billion. The company's GAAP EPS was $0.09, while adjusted EPS was $0.45, which included a negative impact of approximately $0.04 due to Italian payback provisions. For the full year, net sales grew by 6.7% to $12.682 billion, with GAAP EPS at $0.45 and adjusted EPS at $1.71.

Boston Scientific reported net sales of $3.170 billion, representing an 8.1% increase on a reported basis, a 13.7% increase on an operational basis, and an 11.5% increase on an organic basis compared to the prior year period. The company's GAAP net income available to common stockholders was $174 million, or $0.12 per share, while adjusted EPS reached $0.43.

Boston Scientific reported net sales of $3.244 billion for Q2 2022, representing a 5.4% increase on a reported basis and a 6.6% increase on an organic basis compared to the prior year period. The company's GAAP net income available to common stockholders was $246 million, or $0.17 per share, while adjusted EPS reached $0.44.

Boston Scientific reported net sales of $3.026 billion for the first quarter of 2022, representing a 10.0% increase on a reported basis and an adjusted EPS of $0.39. The company's growth was fueled by strong execution, an innovative portfolio, and improved procedure volume.

Boston Scientific reported net sales of $3.127 billion for Q4 2021, a 15.4% increase year-over-year. GAAP net income available to common stockholders was $80 million, or $0.06 per share, while adjusted EPS reached $0.45. The company's performance was driven by growth across all reportable segments and regions.

Boston Scientific reported net sales of $2.932 billion for Q3 2021, representing a 10.3% increase on a reported basis and a 10.6% increase on an organic basis. GAAP net income available to common stockholders was $0.28 per share, compared to a net loss of $(0.12) per share in the prior year, with adjusted EPS reaching $0.41. The company's growth strategy and recent acquisitions have positioned it well for long-term success.

Boston Scientific reported strong second-quarter results with net sales of $3.077 billion, a 53.6% increase year-over-year. GAAP EPS was $0.12, and adjusted EPS was $0.40, exceeding guidance. The company experienced faster-than-market growth in most segments.

Boston Scientific announced strong first-quarter results, with net sales reaching $2.752 billion, reflecting an 8.2% increase. The company's GAAP net income was $327 million, or $0.23 per share, and adjusted EPS was $0.37. The company also updated its full year and Q2 2021 guidance.

Boston Scientific reported Q4 2020 net sales of $2.708 billion, a decrease of (6.8) percent compared to the prior year period. GAAP net income available to common stockholders was $138 million, or $0.10 per share, while adjusted EPS was $0.23. The results were impacted by the WATCHMAN conversion and the LOTUS Edge recall.

Boston Scientific reported Q3 2020 sales of $2.659 billion, a decline of 1.8% on a reported basis compared to the prior year. The company experienced a GAAP net loss of $(169) million or $(0.12) per share, while achieving an adjusted EPS of $0.37.

Boston Scientific reported a decline in sales and a GAAP loss for the second quarter of 2020, primarily due to the impact of the COVID-19 pandemic. However, the company saw business recovering over the course of the quarter and achieved adjusted earnings per share of $0.08.

Boston Scientific's Q1 2020 sales reached $2.543 billion, reflecting growth on a reported and operational basis, but a decline on an organic basis. GAAP earnings per share decreased, while adjusted earnings per share also saw a reduction compared to the prior year. The company withdrew its Q1 2020 sales and EPS guidance due to the COVID-19 pandemic.

Boston Scientific reported strong Q4 2019 results, with sales reaching $2.905 billion, a 13.4% increase. GAAP EPS was $2.83, and adjusted EPS was $0.46, surpassing guidance. Revenue growth was seen across all segments and regions.